KIT and gastrointestinal stromal tumor: When comparing biochemical inhibition of KIT mutants in exon 11, exon 13, and exon 17 with highest frequency in patients with GIST according to the American Association for Cancer Research Genie database (Supplementary Table S3; ref. 35), M4205 shows superior activity versus sunitinib for activation loop mutants (exon 17) and is significantly more potent than ripretinib against ATP pocket mutants (exon 13).